Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.

Author(s): Force E, Taberner F, Cabellos C, Ribes S, Domenech A, Tubau F, Viladrich PF, Gudiol F

Affiliation(s): Hospital Universitari de Bellvitge, Barcelona, Spain.

Publication date & source: 2009-07, Eur J Clin Microbiol Infect Dis., 28(7):807-11. Epub 2009 Feb 17.

Publication type: Comparative Study; Research Support, Non-U.S. Gov't

Meropenem is a broad-spectrum carbapenem antibiotic that is highly active against the pathogens causing meningitis. The aims of this study was to determine the efficacies of meropenem alone and combined with rifampin against two Streptococcus pneumoniae strains with different susceptibility to beta-lactams using the guinea pig meningitis model and compare them with the standard ceftriaxone plus vancomycin therapy. All treatments except rifampin were bactericidal from 6 h. The addition of rifampin did not improve the activity of meropenem alone. Our results provide good evidence of the efficacy of meropenem in the treatment of penicillin- and cephalosporin-susceptible and -resistant pneumococcal meningitis similar to that of ceftriaxone plus vancomycin, suggesting that meropenem might be a good option in the management of this infection.